Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.33 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.30 |
| ▸ | CPT1A | P50416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29839991 | 0.87 | CA4 (0.38) | CA4BBOX1SLC22A16CPT2CPT1A | |
| SCHEMBL30201053 | 0.83 | CA4 (0.41) | CA4BBOX1SLC22A16CPT2CPT1A | |
| SCHEMBL30065458 | 0.82 | CA4 (0.37) | CA4SLC22A16CPT2CPT1A | |
| SCHEMBL29652006 | 0.81 | BLM (0.37) | CA4BBOX1 | |
| SCHEMBL29623630 | 0.80 | CA4 (0.38) | CA4BBOX1SLC22A16CPT2CPT1A | |
| SCHEMBL29840031 | 0.80 | CA4 (0.38) | CA4BBOX1SLC22A16CPT2CPT1A | |
| SCHEMBL29840028 | 0.80 | CA4 (0.38) | CA4BBOX1SLC22A16CPT2CPT1A | |
| SCHEMBL29780359 | 0.79 | CA4 (0.37) | CA4BBOX1SLC22A16CPT2CPT1A | |
| SCHEMBL30160923 | 0.74 | CA4 (0.46) | CA4BBOX1SLC22A16CPT2CPT1A | |
| SCHEMBL29497518 | 0.74 | CA4 (0.46) | CA4BBOX1SLC22A16CPT2CPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4319746-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | Hemoshear Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022216848-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | Hemoshear Therapeutics, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | disclosed |